Headlines about Sinovac Biotech (NASDAQ:SVA) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Sinovac Biotech earned a news impact score of 0.11 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 45.9564995453523 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Sinovac Biotech (SVA) traded up $0.02 during trading on Friday, hitting $8.06. 36,600 shares of the stock traded hands, compared to its average volume of 84,667. The firm has a market capitalization of $459.51, a PE ratio of 25.19 and a beta of 0.13. Sinovac Biotech has a 12 month low of $4.60 and a 12 month high of $8.11.
Sinovac Biotech (NASDAQ:SVA) last announced its earnings results on Wednesday, November 22nd. The biopharmaceutical company reported $0.08 EPS for the quarter.
Separately, BidaskClub raised shares of Sinovac Biotech from a “hold” rating to a “buy” rating in a research note on Friday, November 3rd.
ILLEGAL ACTIVITY WARNING: This news story was posted by TrueBlueTribune and is the property of of TrueBlueTribune. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.truebluetribune.com/2018/01/19/sinovac-biotech-sva-earns-news-sentiment-rating-of-0-11.html.
About Sinovac Biotech
Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps.
Receive News & Ratings for Sinovac Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinovac Biotech and related companies with MarketBeat.com's FREE daily email newsletter.